Kailera Therapeutics, a clinical-stage biopharma startup making oral and injectable obesity treatments, raised a $600 million Series B led by Bain Capital.
Why it matters: Weight loss drugs continue to dominate biotech deals as investors predict strong demand for improved treatments.
